{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=EYLEA+%28Aflibercept%29+intravitreal+injection", "query": { "intervention": "EYLEA (Aflibercept) intravitreal injection" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 169, "total_pages": 17, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=EYLEA+%28Aflibercept%29+intravitreal+injection&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-10-01T18:59:23.322Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02387957", "title": "A 24 Month Phase 2a Open Label, Randomized Study of Avastin®, Lucentis®, or Eylea® (Anti-VEGF Therapy) Administered in Combination With Fovista® (Anti-PDGF BB Pegylated Aptamer)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Age-Related Macular Degeneration" ], "interventions": [ { "name": "Fovista®", "type": "DRUG" }, { "name": "bevacizumab", "type": "DRUG" }, { "name": "ranibizumab", "type": "DRUG" }, { "name": "aflibercept", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ophthotech Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": null, "sex": "ALL", "summary": "50 Years and older" }, "enrollment_count": 63, "start_date": "2016-04-26", "completion_date": "2017-01", "has_results": true, "last_update_posted_date": "2024-10-30", "last_synced_at": "2026-10-01T18:59:23.322Z", "location_count": 24, "location_summary": "Phoenix, Arizona • Beverly Hills, California • Sacramento, California + 21 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Santa Ana", "state": "California" }, { "city": "New London", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT02387957" }, { "nct_id": "NCT04469595", "title": "A Study of Intravitreal ILUVIEN® Implant as Baseline Therapy in Patients With Early Diabetic Macular Edema (DME)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Diabetic Macular Edema" ], "interventions": [ { "name": "Iluvien 0.19 MG Drug Implant", "type": "DRUG" }, { "name": "Aflibercept", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Alimera Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 300, "start_date": "2020-08-31", "completion_date": "2024-12-31", "has_results": false, "last_update_posted_date": "2024-07-31", "last_synced_at": "2026-10-01T18:59:23.322Z", "location_count": 40, "location_summary": "Phoenix, Arizona • Tucson, Arizona • Beverly Hills, California + 36 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Glendale", "state": "California" }, { "city": "Laguna Hills", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04469595" }, { "nct_id": "NCT01521559", "title": "Study to Assess the Clinical Efficacy and Safety of Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) in Patients With Branch Retinal Vein Occlusion (BRVO)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Branch Retinal Vein Occlusion" ], "interventions": [ { "name": "Macular Laser Photocoagulation", "type": "PROCEDURE" }, { "name": "Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321)", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "Regeneron Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 183, "start_date": "2012-04", "completion_date": "2014-03", "has_results": true, "last_update_posted_date": "2014-11-13", "last_synced_at": "2026-10-01T18:59:23.322Z", "location_count": 45, "location_summary": "Phoenix, Arizona • Tucson, Arizona • Beverly Hills, California + 42 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Beverly Hills", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Mountain View", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01521559" }, { "nct_id": "NCT03249740", "title": "A Depot Formulation of Sunitinib Malate (GB-102) in Subjects With Neovascular (Wet) Age-related Macular Degeneration", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Neovascular Age-Related Macular Degeneration" ], "interventions": [ { "name": "GB-102", "type": "DRUG" }, { "name": "Aflibercept", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Graybug Vision", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": null, "sex": "ALL", "summary": "50 Years and older" }, "enrollment_count": 32, "start_date": "2017-08-29", "completion_date": "2019-01-16", "has_results": false, "last_update_posted_date": "2019-12-20", "last_synced_at": "2026-10-01T18:59:23.322Z", "location_count": 8, "location_summary": "Gilbert, Arizona • Beverly Hills, California • Indianapolis, Indiana + 5 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Lynbrook", "state": "New York" }, { "city": "Abilene", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03249740" }, { "nct_id": "NCT01909791", "title": "Treatment for CI-DME in Eyes With Very Good VA Study", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Diabetic Macular Edema" ], "interventions": [ { "name": "Prompt Laser", "type": "PROCEDURE" }, { "name": "Prompt aflibercept", "type": "DRUG" }, { "name": "Deferred laser", "type": "PROCEDURE" }, { "name": "Deferred aflibercept", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "Jaeb Center for Health Research", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 702, "start_date": "2013-10", "completion_date": "2018-09-11", "has_results": true, "last_update_posted_date": "2020-07-31", "last_synced_at": "2026-10-01T18:59:23.322Z", "location_count": 100, "location_summary": "Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 84 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Campbell", "state": "California" }, { "city": "Loma Linda", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01909791" }, { "nct_id": "NCT02949024", "title": "Suprachoroidal Injection of CLS-TA Alone or With Aflibercept in Subjects With Diabetic Macular Edema", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Diabetic Macular Edema" ], "interventions": [ { "name": "IVT Aflibercept", "type": "DRUG" }, { "name": "SC CLS-TA", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Clearside Biomedical, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2016-11-10", "completion_date": "2017-10-17", "has_results": true, "last_update_posted_date": "2021-05-13", "last_synced_at": "2026-10-01T18:59:23.322Z", "location_count": 2, "location_summary": "Mountain View, California • The Woodlands, Texas", "locations": [ { "city": "Mountain View", "state": "California" }, { "city": "The Woodlands", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02949024" }, { "nct_id": "NCT01805297", "title": "Aflibercept Injection for Proliferative Diabetic Retinopathy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Vitreous Hemorrhage" ], "interventions": [ { "name": "Intravitreal Aflibercept Injection", "type": "DRUG" }, { "name": "Standard Vitrectomy", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "University of Oklahoma", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 12, "start_date": "2013-03", "completion_date": "2015-11", "has_results": true, "last_update_posted_date": "2023-12-27", "last_synced_at": "2026-10-01T18:59:23.322Z", "location_count": 1, "location_summary": "Oklahoma City, Oklahoma", "locations": [ { "city": "Oklahoma City", "state": "Oklahoma" } ], "official_url": "https://clinicaltrials.gov/study/NCT01805297" }, { "nct_id": "NCT02307682", "title": "Efficacy and Safety of RTH258 Versus Aflibercept - Study 1", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Neovascular Age-Related Macular Degeneration", "Choroidal Neovascularization" ], "interventions": [ { "name": "Brolucizumab ophthalmic solution", "type": "DRUG" }, { "name": "Aflibercept ophthalmic solution", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Alcon Research", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": null, "sex": "ALL", "summary": "50 Years and older" }, "enrollment_count": 1775, "start_date": "2014-12-08", "completion_date": "2018-03-28", "has_results": true, "last_update_posted_date": "2025-01-16", "last_synced_at": "2026-10-01T18:59:23.322Z", "location_count": 1, "location_summary": "Fort Worth, Texas", "locations": [ { "city": "Fort Worth", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02307682" }, { "nct_id": "NCT01926977", "title": "Evaluation of Pain and Inflammation After Injection of Lucentis vs Eylea for Treatment of Wet Macular Degeneration", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Neovascular Age-Related Macular Degeneration" ], "interventions": [ { "name": "Ranibizumab 0.5mg", "type": "DRUG" }, { "name": "Aflibercept 2.0mg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Arshad Khanani", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "65 Years", "maximum_age": null, "sex": "ALL", "summary": "65 Years and older" }, "enrollment_count": 100, "start_date": "2013-09", "completion_date": "2014-05", "has_results": true, "last_update_posted_date": "2016-03-03", "last_synced_at": "2026-10-01T18:59:23.322Z", "location_count": 1, "location_summary": "Reno, Nevada", "locations": [ { "city": "Reno", "state": "Nevada" } ], "official_url": "https://clinicaltrials.gov/study/NCT01926977" }, { "nct_id": "NCT06011798", "title": "Assess the Efficacy and Safety of Repeat Intravitreal Injections of Foselutoclax (UBX1325) in Patients With DME (ASPIRE)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Diabetic Macular Edema", "Retinal Disease", "Macular Edema", "Diabetes Mellitus", "Diabetic Retinopathy", "Retinal Degeneration", "Retinal Diseases", "Eye Diseases", "Edema" ], "interventions": [ { "name": "Aflibercept", "type": "DRUG" }, { "name": "foselutoclax", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Unity Biotechnology, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 52, "start_date": "2023-08-23", "completion_date": "2025-04-08", "has_results": true, "last_update_posted_date": "2025-08-05", "last_synced_at": "2026-10-01T18:59:23.322Z", "location_count": 19, "location_summary": "Bakersfield, California • Beverly Hills, California • Huntington Beach, California + 16 more", "locations": [ { "city": "Bakersfield", "state": "California" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Huntington Beach", "state": "California" }, { "city": "Walnut Creek", "state": "California" }, { "city": "Longmont", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT06011798" } ] }